Last updated: May 12, 2026
Optiray 300 (iopamidol 300 mgI/mL) clinical trials update, market analysis, and projection
Executive summary: Optiray 300 (iopamidol injection, 300 mgI/mL) is a low-osmolar, non-ionic iodinated contrast agent (i.v.) used for CT and angiography. Public, label-linked late-stage development activity for “Optiray 300” as a branded product is limited; the competitive market is driven by generic iopamidol and other low-osmolar iodinated contrast agents. Pricing and volume are shaped by hospital group purchasing, tendering, and payer/provider conversion to formulary equivalents. Near-to-mid-term market outlook is modest: continued demand growth is mainly volume-driven (imaging utilization), while brand economics face downward pressure from generics and therapeutically interchangeable products rather than new clinical entrants.
What clinical trials have been completed or ongoing for Optiray 300 (iopamidol 300 mgI/mL)?
Direct branded “Optiray 300” late-stage trials: Public trial registrations tied specifically to Optiray 300 have been sparse versus broader iopamidol development and generic-bioequivalence programs. Most “clinical” activity relevant to the product is category-level (iodinated contrast safety and dosing) and regulatory rather than new mechanism or new indication testing.
Where iopamidol trial activity typically clusters
- Contrast-associated acute adverse reactions (hypersensitivity, vasovagal events, nausea, pain at injection site)
- Contrast-induced acute kidney injury risk mitigation (screening, hydration strategies, risk stratification in at-risk populations)
- Protocol optimization for imaging (dose, injection rate, catheter selection, timing for CT angiography)
- Comparative safety and tolerability between non-ionic iodinated agents (often real-world or randomized equivalence designs)
Key clinical endpoints used across iopamidol studies
- Incidence of immediate hypersensitivity reactions
- Change in renal function markers (e.g., serum creatinine, eGFR) within defined windows
- Serious adverse events and treatment-emergent adverse events
- Imaging quality endpoints (contrast enhancement adequacy, diagnostic confidence)
- Use of prophylaxis (IV hydration, medication pre-treatment) and downstream outcomes
Practical read-through for current R&D posture
- For iopamidol, incremental clinical differentiation is difficult because (1) it is a widely used, chemically defined small molecule and (2) most differentiation moves to packaging, concentration/dose presentation, and manufacturing rather than novel clinical claims.
What do recent safety and renal-risk studies mean for iopamidol 300 (Optiray 300) utilization?
Renal-risk management remains the main clinical lever
In iodinated contrast practice, iopamidol’s clinical standing rests on established precautions for patients at higher risk of contrast-associated AKI:
- pre-exposure assessment (baseline renal function and comorbidities)
- use of hydration protocols
- avoidance of nephrotoxic co-medications where feasible
- judicious contrast dose selection and imaging necessity review
How this affects formularies
Hospitals align contrast selection with:
- institution-specific AKI prevention pathways
- product availability and tender pricing
- safety incident reporting patterns and pharmacy committee decisions
Bottom-line market implication
Safety is “table stakes.” Product decisions are increasingly procurement-led rather than driven by new clinical evidence.
Which patents or exclusivity do (or did) govern Optiray 300, and how does that shape generic entry?
Brand economics are governed by legacy small-molecule exclusivity
Optiray 300 is an established contrast agent whose patent estate, if any, is largely outlived or narrowed to specific formulation, manufacturing, or packaging claims rather than broad active-ingredient exclusivity. The commercial implication is straightforward:
- generic and authorized-equivalent iopamidol entries compete strongly
- brand share depends on supply reliability, contracting, and pharmacy channel relationships
Typical IP structures for older iodinated contrast brands
- process patents (manufacturing conditions, purification steps)
- container/closure and fill-finish claims
- packaging and dosing system claims
- narrow additional medical use claims, if any, rather than composition-of-matter exclusivity
Featured-snippet takeaway
For an established iopamidol concentration like 300 mgI/mL, ongoing exclusivity barriers are usually minimal for therapeutically equivalent generics; competition is procurement-driven.
What is the competitive landscape for Optiray 300, and how does iopamidol 300 mgI/mL compare with alternatives?
Market segmentation
- Iodinated low-osmolar contrast agents (LOCA): iopamidol and comparable non-ionic agents
- Higher-concentration formulations: often selected for dose efficiency, catheter throughput, and imaging protocol needs
- Alternative contrast classes: gadolinium-based agents for MRI, and other modalities (less direct substitution)
Competitive substitution logic
Radiology departments often substitute between iodinated LOCA products based on:
- tender pricing per vial/volume
- product handling and shelf availability
- availability of equivalent injection protocols (flow rate characteristics)
- institutional clinical pathway alignment
Competitive set (class-level)
The most direct substitutes are other non-ionic iodinated low-osmolar contrast agents used for CT and angiography. Actual formulary outcomes depend on:
- group purchasing organization contracts
- national and regional distribution pricing
- supply constraints and backorders (which can temporarily shift use between equivalent products)
Featured-snippet takeaway
Optiray 300 competes as a class interchangeable iodinated contrast. Differentiation is usually non-clinical at the point of purchase.
What is the FDA regulatory status of Optiray 300 and how does it affect market access?
Regulatory pathway context
Optiray 300 (iopamidol injection) is an FDA-approved iodinated contrast product with established labeling covering dosing, warnings (including hypersensitivity and renal risk), and imaging indications consistent with iodinated contrast use.
How generic and authorized equivalents enter
- Generic competition typically follows an abbreviated pathway grounded in bioequivalence and same active ingredient and concentration.
- Market access depends on FDA approval and commercialization through wholesalers and group purchasing contracts.
Practical effect
Once generics are on-contract, the branded product’s volume tends to decline unless it maintains pricing power through contract leverage or supply assurance.
How fast is the iodinated contrast market growing, and what portion is attributable to CT utilization?
Market growth drivers (category-level)
- growth in CT imaging volumes globally
- aging populations and rising prevalence of conditions requiring cross-sectional imaging
- protocol standardization and increased throughput
- increased use of CT angiography
Market headwinds
- aggressive contracting and tender-based pricing
- increased generic adoption
- operational supply chain pressure that can shift product usage temporarily
Net effect for Optiray 300
Because Optiray 300 faces generic headwinds, category volume growth does not fully translate into branded revenue growth. Branded share often declines faster than total category volume rises.
Revenue projection for Optiray 300: baseline, downside, and upside scenarios
What must drive projection
For an established, generic-exposed small molecule contrast agent, projections depend on:
- branded share of total iopamidol 300 mgI/mL usage
- average net price after rebates and wholesaler/contract discounts
- utilization growth in CT and angiography
- competitive pricing intensity and generic supply stability
Scenario framework (how to model)
- Baseline: stable branded contract participation with modest share drift to generics, offset by category growth.
- Downside: intensified tendering pushes further share loss; average net price declines faster than volume increases.
- Upside: contract retention plus supply reliability allows slower share erosion; occasional supply disruptions at competing products raise short-term uptake.
Quantification constraint
Public sources were not cited in this response because the request did not provide a geography scope, timeframe, or the specific data source set needed to support exact numeric projections.
What generic entry risks exist for Optiray 300 in the US and other jurisdictions?
US risk profile
- Once a branded iodinated contrast faces authorized generic and multiple generic manufacturers, additional entrants usually track capacity and compliance rather than differentiated claims.
- Entry risk concentrates on pricing and supply, not clinical differentiation.
Non-US risk profile
- Pricing controls, tender systems, and import competition can move quickly after regulatory approvals for equivalents.
- Substitution policies at hospital level can change within contract cycles.
Featured-snippet takeaway
For Optiray 300, “entry risk” is mostly share loss risk driven by contracting and competitive supply, rather than new clinical differentiation.
What formulation, method-of-use, or manufacturing patents could still matter for Optiray 300?
Likely residual patent categories
- manufacturing/process changes that improve yield or reduce impurities
- fill-finish or container-closure stability claims
- product-specific particulate control and sterility assurance methods
- packaging configurations for high-throughput clinical workflows
Commercial effect
If remaining patents exist, they tend to affect:
- the ability of a rival to manufacture at scale under a clear freedom-to-operate pathway
- launch timing for a new generic supplier
- licensing cost for market entrants
Featured-snippet takeaway
Even where composition-of-matter exclusivity is exhausted, residual manufacturing or packaging claims can create narrow barriers, but they rarely stop competitive erosion in established contrast categories.
What patent litigation or settlements have affected iopamidol 300 mgI/mL brands (including Optiray 300)?
Branded contrast litigation pattern
For legacy small molecules, litigation typically involves:
- ANDA paragraph IV challenges (if any actionable unexpired patents existed)
- infringement disputes around formulation/manufacturing patents
- settlement-driven launch timing and “carve-out” patent licenses
Relevance to Optiray 300
Branded contrast agents generally experience intermittent litigation during periods when narrower patents are asserted. The commercial outcome usually resolves into:
- delayed generic launch until a particular patent expires
- or settlement permitting launch with label or manufacturing scope constraints
Featured-snippet takeaway
For a mature agent like iopamidol 300 mgI/mL, the litigation risk tends to be lower than generic supply and contract dynamics.
How does Optiray 300 compare with other iodinated contrast dosing strategies (300 vs 240 vs 370 mgI/mL)?
Clinical selection is protocol-driven
- higher iodinated concentration can reduce volume for the same iodine delivery, relevant when catheter injection volume limits exist
- lower concentrations can be selected to reduce volume burden, especially in patients where total fluid volume matters
Market effect
Because multiple concentrations exist, branded share for one concentration is partly influenced by:
- whether formularies standardize on a single concentration
- whether radiology protocols change to optimize dose/volume tradeoffs
Bottom-line for Optiray 300
Optiray 300 competes not only with other iopamidol products but also with alternative concentrations and alternative iodinated low-osmolar agents.
What should investors and commercial teams monitor for Optiray 300 over the next 12–36 months?
Commercial KPIs
- contract wins/losses in major hospital systems and GPO channels
- average net price trajectory (not list price)
- inventory availability and backorder rates
- competitive share shifts tied to tender cycles
- adverse event signals that drive formulary review
Regulatory and operational KPIs
- new generic approvals tied to iopamidol 300 mgI/mL
- manufacturing site changes and FDA inspection outcomes
- supply disruptions affecting distribution
Clinical KPIs
- adoption of institutional AKI-prevention pathways
- protocol changes for CT angiography and contrast dosing
Key Takeaways
- Optiray 300 (iopamidol 300 mgI/mL) is a mature, widely substituted iodinated contrast agent where differentiation is primarily procurement and supply reliability rather than new clinical performance.
- Clinical evidence supporting safe renal-risk management and hypersensitivity precautions is already standard-of-care; incremental branded trials are limited in practice.
- The near-to-mid-term market outlook is modest and volume-driven, with branded revenue constrained by generic and therapeutically interchangeable alternatives and tender-based pricing.
- The biggest commercial determinants for Optiray 300 are contract dynamics, average net price, supply continuity, and hospital formulary substitution policies.
FAQs
- Does iopamidol 300 mgI/mL have different formulary placement than iopamidol 370 mgI/mL?
- How do hydration protocols and AKI risk screening influence iodinated contrast selection among competing LOCA products?
- What is the typical lead time from generic approval to hospital formulary uptake for established iodinated contrast agents?
- Do supply shortages in one iodinated contrast agent lead to sustained share gains for substitutes like Optiray 300?
- What packaging or concentration-specific differences most affect hospital procurement decisions for CT contrast?
References
No sources were cited because the response was constrained to the information provided in the prompt and did not include verifiable FDA/regulatory, trial registry, or market-size figures tied to Optiray 300.
